Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Time to Prescribe Dual instead of Mono

  • Choi, Joon Young (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2021.02.15
  • Accepted : 2021.03.10
  • Published : 2021.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016;21:14-23. https://doi.org/10.1111/resp.12660
  2. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34. https://doi.org/10.1056/NEJMoa1516385
  3. Rhee CK, Yoshisue H, Lad R. Fixed-dose combinations of long-acting bronchodilators for the management of COPD: global and Asian perspectives. Adv Ther 2019;36:495-519. https://doi.org/10.1007/s12325-019-0893-3
  4. Lee SH, Rhee CK, Yoo K, Park JW, Yong SJ, Kim J, et al. Direct switch from tiotropium to indacaterol/glycopyrronium in chronic obstructive pulmonary disease patients in Korea. Tuberc Respir Dis 2021;84:96-104. https://doi.org/10.4046/trd.2020.0109
  5. Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis 2019;14:249-60. https://doi.org/10.2147/COPD.S185485
  6. Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res 2017;18:140. https://doi.org/10.1186/s12931-017-0622-x
  7. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94. https://doi.org/10.1183/09031936.00200212
  8. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209. https://doi.org/10.1016/S2213-2600(13)70052-3
  9. Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig 2016;54:428-35. https://doi.org/10.1016/j.resinv.2016.06.006
  10. Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naive COPD patients: a pooled analysis. Respirology 2020;25:393-400. https://doi.org/10.1111/resp.13651
  11. 2020 Global strategy for prevention, diagnosis and managment of COPD [Internet]. Fontana, WI: Global Initiative for Chronic Obstructive Lung Disease; 2020 [cited 2020 Dec 10]. Available from: https://goldcopd.org/gold-reports/.